Evidence map›Paper›PMID 40882477›Full record

ArticleComputers in biology and medicine2025

Dona Flor and her two husbands: Discovery of novel HDAC6/AKT2 inhibitors for myeloid cancer treatment.

Karoline B Waitman, Holli-Joi Martin, Jorge A E G Carlos, Rodolpho C Braga, Vinícius A M Souza, Cleber C Melo-Filho, Sebastian Hilscher, Mônica F Z J Toledo, Maurício T Tavares, Letícia V Costa-Lotufo and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Computers in biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Karoline B WaitmanDepartment of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Holli-Joi MartinLaboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, United States.
Jorge A E G CarlosBiomedical Science Institute, Department of Pharmacology, University of São Paulo (USP), São Paulo, Brazil.
Rodolpho C BragaInsilicAll, Sao Paulo, SP, Brazil.
Vinícius A M SouzaDepartment of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Cleber C Melo-FilhoLaboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, United States.
Sebastian HilscherFaculty of Biosciences, Martin-Luther-University of Halle-Wittenberg, Halle (Saale), Germany.
Mônica F Z J ToledoDepartment of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Maurício T TavaresDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02115, United States; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, United States.
Letícia V Costa-LotufoBiomedical Science Institute, Department of Pharmacology, University of São Paulo (USP), São Paulo, Brazil.
João A Machado-NetoInsilicAll, Sao Paulo, SP, Brazil.
Mike SchutkowskiFaculty of Biosciences, Martin-Luther-University of Halle-Wittenberg, Halle (Saale), Germany.
Wolfgang SipplFaculty of Biosciences, Martin-Luther-University of Halle-Wittenberg, Halle (Saale), Germany.
Thales KronenbergerInterfaculty Institute of Microbiology and Infection Medicine (IMIT), University of Tübingen, Germany; Partner-site Tübingen, German Center for Infection Research (DZIF), Tübingen, Germany, Tubingen, 72076, Germany; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, 70211, Finland.
Vinicius M AlvesLaboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, United States.
Roberto Parise-FilhoDepartment of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: roberto.parise@usp.br.
Eugene N MuratovLaboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, United States; Cheminformatics Laboratory, Department of Chemistry, Center for Exact and Natural Sciences (CCEN), Federal University of Paraíba (UFPB), Campus I Lot. Cidade Universitária, Castelo Branco, 58051-900, João Pessoa, Paraíba, Brazil. Electronic address: murik@email.unc.edu.

Funding

Enabling the Accelerated Discovery of Novel Chemical Probes by Integration of Crystallographic, Computational, and Synthetic Chemistry ApproachesR01GM140154 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TROPSHA, ALEXANDER, WILLSON, TIMOTHY M · 2021 to 2024
$2.4M
NIGMS NIH HHS R01 GM140154
6 · The paper itself

Abstract

The treatment of hematological cancers with hybrid kinase and histone deacetylase (HDAC) inhibitors represents a novel strategy to overcome acquired drug resistance. We curated half-maximal inhibitory concentration (IC

Indexed as

Antineoplastic AgentsDrug DiscoveryHistone Deacetylase 6Histone Deacetylase InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktCell Line, TumorHumansAntineoplastic AgentsHDAC6 protein, humanHistone Deacetylase 6Histone Deacetylase InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktBenzamidesHematological cancerHistone deacetylaseHybrid inhibitorsHydroxamic acidsKinaseQSARVirtual screening

Identifiers

PMID40882477
PMCPMC12619660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.